Cell Reports vs PLOS ONE in 2026: When Selectivity Matters and When It Doesn't

Understanding the editorial model is more useful than comparing impact factors.

Cell Reports asks: "Does this paper advance mechanistic understanding of biology?" Editors look for a clear biological story with experimental evidence showing how something works at the cellular or molecular level. Descriptive work without a mechanism doesn't fit. Characterization studies without functional follow-up get desk-rejected. The editorial team makes desk decisions in about 5 days, they know immediately whether a paper fits their scope.

PLOS ONE asks: "Is this research technically sound?" The journal evaluates methodology, data quality, reproducibility, and whether conclusions are supported by evidence. It explicitly does not evaluate for perceived importance, novelty, or whether the findings will change the field. This isn't a lower standard, it's a different standard. The 31% acceptance rate (down from 68% a decade ago) reflects stricter initial screening, not a change in the review philosophy.

Career signal in biology. A Cell Reports publication tells hiring committees and grant reviewers that your work was evaluated for novelty by Cell Press editors. For faculty searches in cell biology, developmental biology, or molecular biology, this distinction matters. Hiring committees understand the difference between journals that gate on novelty and journals that gate on soundness.

The Cell Press transfer system. Papers rejected from Cell, Molecular Cell, Cell Stem Cell, or other Cell Press titles can transfer to Cell Reports with reviews intact. This saves 2-3 months of re-review time. If you're aiming at Cell and the editors say "strong but not broad enough," Cell Reports is the built-in landing spot.

Impact factor leverage. At 6.9, Cell Reports sits above the threshold that many grant agencies and promotion committees treat as "high-impact." In many institutional metrics systems, 6.9 and 2.6 fall on different sides of a meaningful line.

Field-specific audience. Cell Reports' ~1,000 papers per year means each paper gets more relative attention within the cell biology community. PLOS ONE's 25,000 papers per year means higher competition for attention, even with good indexing.

Speed and cost. PLOS ONE's median first decision is 42 days. The APC is $1,695, less than a third of Cell Reports' $5,790. For researchers who need a publication timeline they can plan around and a cost their lab can absorb without institutional OA agreements, PLOS ONE is dramatically more accessible.

No novelty requirement. This is the central philosophical difference. PLOS ONE publishes negative results, replication studies, methodological validations, and incremental but rigorous contributions. These papers are scientifically valuable but don't survive novelty-gated journals. Forcing a novelty argument onto work that doesn't naturally have one usually makes the paper weaker, not stronger.

Broader scope. PLOS ONE accepts work across all scientific disciplines. Interdisciplinary papers that don't fit a single-discipline journal's scope have a natural home. Cell Reports only takes cell and molecular biology.

Institutional fee coverage. PLOS has agreements with many universities and library systems that eliminate or reduce the APC. Starting January 2025, PLOS expanded "All-In" unlimited publishing agreements with participating institutions. Check whether your institution has a PLOS agreement before comparing sticker prices.

Declining stigma. PLOS ONE's reputation has improved significantly since the early mega-journal era. The 31% acceptance rate (vs 68% a decade ago) means the journal is now more selective than many field-specific journals. A PLOS ONE publication in 2026 carries more weight than the same publication in 2016.

For a postdoc competing for faculty positions: Cell Reports is worth the extra time and cost if the novelty argument holds. A Cell Press publication signals competitive research to search committees. If the novelty argument is borderline, though, a 3-month rejection cycle at Cell Reports followed by resubmission to PLOS ONE costs more career time than going directly to PLOS ONE.

For a mid-career researcher: Publishing a dataset, methodological comparison, or follow-up study in PLOS ONE is the pragmatic choice. The career signal of Cell Reports matters less when your CV already demonstrates competitiveness. Getting the work published efficiently matters more.

For a graduate student: If this paper will be part of your thesis and your advisor agrees the novelty is there, Cell Reports is worth trying. If the paper is your third or fourth chapter and you need it published to defend, PLOS ONE's faster timeline may be more valuable than the IF difference.

• The paper has a clear mechanistic story in cell or molecular biology
• You can articulate what the reader learns about how something works
• The Cell Press transfer system is relevant (you're already in that ecosystem)
• The career signal matters (faculty search, grant application, tenure case)
• Your institution covers the $5,790 APC through an OA agreement

• The work is technically rigorous but the novelty argument is honest-to-God borderline
• You're publishing negative results, replication data, or methodological work
• The paper is interdisciplinary and doesn't fit a single-discipline scope
• Speed and cost matter more than the IF signal
• You need a predictable timeline (42-day median first decision)
• Your institution has a PLOS "All-In" agreement that eliminates the APC

If you're not sure which journal fits, this order saves the most time:

1. Run the Cell Reports vs. PLOS ONE scope check to assess whether the novelty argument holds
2. If the scan flags novelty as a weakness, go directly to PLOS ONE
3. If novelty scores well, try Cell Reports first with the understanding that a desk rejection comes in ~5 days
4. If Cell Reports rejects, reformat for PLOS ONE, you've lost 1-2 weeks, not months

A Cell Reports vs. PLOS ONE scope check takes 60 seconds and prevents the most common mistake: spending 3 months in Cell Reports review only to end up at PLOS ONE anyway.